- Home
- HWH vs HOTH Comparison
HWH vs HOTH Comparison
Compare HWH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HWH | HOTH |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 11.7M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HWH | HOTH |
|---|---|---|
| Price | $1.09 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.6K | ★ 333.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.37 | 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $866,926.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.49 |
| 52 Week High | $7.77 | $2.12 |
Technical Indicators
Market Signals| Indicator | HWH | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 49.69 |
| Support Level | $0.99 | $0.49 |
| Resistance Level | $1.20 | $0.80 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 65.60 | 69.69 |
Price Performance
Historical ComparisonAbout HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.